FDA Orders 23andMe to Halt Sales

at 9:00 AM
Save ArticleSave Article

Failed to save article

Please try again

 (Scott Beale/Flickr)

The Food and Drug Administration has ordered Silicon Valley gene-testing service 23andMe to halt all sales and marketing of its gene testing kits. 23andMe led the way in the personal-genomics revolution after it was declared Time Magazine's 2008 invention of the year, but regulators have concerns that inaccurate results from the direct-to-consumer tests, or results that are not adequately understood by patients, could lead to dangerous decisions. Forum discusses the FDA's order and the future of personal gene tests.


Hank Greely, director of the Center for Law and the Biosciences and law professor at Stanford University

Christina Farr, health reporter for Venture Beat

Nita Farahany, professor of genome sciences and policy and law professor at Duke University; also a member of the Presidential Commission for the Study of Bioethical Issues

Courtney Lias, director of chemistry and toxicology devices at the Center for Devices and Radiological Health at the Food and Drug Administration